Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

On October 8, 2024, PhRMA held a media briefing to address growing concerns over the Inflation Reduction Act (IRA) and its effects on the biopharmaceutical industry, Medicare Part D beneficiaries, and ...

And Gilead appears to be reaping the benefits ... Agencies sometimes choose not to list drugs because they cost more than existing treatments that perform equally well or because incremental ...

Since the initial release of Open AI’s Chat GPT in 2022, the adoption of artificial intelligence (AI) technology has spread ...

But NICE said there was a lack of comparator data with standard care of salvage chemotherapy, so it was unable to quantify the exact size of the drug’s benefit. Gilead has kept the list price a ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

High rates of virologic suppression were observed among Black patients who received long-term ART with BIC/FTC/TAF for HIV management.

Gilead Sciences said on Friday it was voluntarily ... to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week. Merck is immune from ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...